Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Prostatic Neoplasms 1Head and Neck Neoplasms 1Adenocarcinoma, Follicular 1

Interventions

Trastuzumab 2Iodine-131 2vandetanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1tipifarnib 1pazopanib 1mercaptoundecahydrododecaborate 1copanlisib 1Vemurafenib 1Triiodothyronine 1Surgical Procedures, Operative 1Spectrum Analysis 1Rosiglitazone 1Radiofrequency Ablation 1Photochemotherapy 1Paclitaxel 1Interleukin-12 Subunit p35 1Interleukin-12 1Imatinib Mesylate 1Famotidine 1Docetaxel 1Congresses as Topic 1Bortezomib 1Azacitidine 14-boronophenylalanine-fructose 12-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a 11-phenyl-3,3-dimethyltriazene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Thyroid Cancer, Papillary × Triiodothyronine × Clear all
NCT00004062 2013-12-19

Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer

National Cancer Institute (NCI)

Phase 1 Completed
EndocrineHead & Neck

Thyroid Cancer, Papillary, Head and Neck Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡